Cleerly, Inc. — Cyborg Score 8/10

Strong
AI-driven cardiovascular diagnostics

Strategic Profile

Cleerly completed a Series C funding round in November 2024, and recently achieved Medicare coverage and a CPT Category I code for advanced plaque analysis, positioning itself as a market leader in AI-enabled cardiovascular diagnostics. As of May 31, 2026, the company has 354 employees, demonstrating significant scaling momentum in a competitive but undersaturated market.

Cyborg Score Rationale

Cleerly commands a strong competitive position with FDA clearance, recent Medicare coverage, substantial funding ($388-578M raised to date), and clinical validation across 40,000+ patients. However, it faces litigation from competitor HeartFlow (April 2026) over AI cardiology technology, which creates near-term execution and reputation risk.

Top Insights

  • FDA-cleared platform with Medicare coverage and CPT Category I code enables rapid commercial scaling and physician adoption in cardiology practices
  • Litigation from HeartFlow (April 2026) over AI technology IP represents near-term risk to commercialization momentum despite strong clinical evidence foundation
  • Recent product enhancement (Cleerly PREVIEW, March 2026) directly addresses prior authorization workflow pain points, differentiating from competitors on operational efficiency
  • Regulatory and reimbursement tailwinds, combined with validated clinical outcomes from 40,000+ patient cohort, create strong competitive moat in prevention-focused cardiology market

Named Competitors

  • HeartFlow — AI-driven coronary CT analysis for ischemia assessment
  • Lantheus — Cardiovascular imaging and diagnostics
  • VentriPoint — Cardiac imaging analysis software

Recent Developments

  • (May 2026) MemorialCare systemwide launch bringing AI-powered assessment to Coronary CTA imaging across Long Beach Medical Center and Orange Coast Medical Center
  • (April 2026) HeartFlow litigation filed over AI cardiology technology claims
  • (March 2026) Launch of Cleerly PREVIEW workflow enhancement at American College of Cardiology (ACC.26) conference to streamline prior authorization and case prioritization
  • (November 2024) Series C funding round completion

Open the full interactive Cleerly, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →